• Vistagen says Phase 3 PALISADE-4 study of fasedienol nasal spray for social anxiety disorder failed to meet its primary endpoint

  Vistagen has announced that the Phase 3 PALISADE-4 public speaking challenge study of intranasal fasedienol (PH94B) for the treatment of social anxiety disorder failed to meet its primary endpoint. In December 2025, the company announced… [Read more . . .]

• Insmed names Samuele Butera as Senior VP, General Manager, Global Respiratory

  Insmed has hired former Johnson & Johnson executive Samuele Butera as Senior VP, General Manager, Global Respiratory, the company said. Butera previously served in executive positions at Sandoz and Novartis before joining Johnson & Johnson,… [Read more . . .]

• Zymeworks to acquire Theravance Biopharma and its Yupelri revefenacin inhalation solution

  Canadian biotech Zymeworks has agreed to pay $17 per share, a total of approximately $929 million, to acquire Theravance Biopharma, the companies have announced. The deal, which is subject to approval by Theravance shareholders, is… [Read more . . .]

• Leyden Labs gets €40 million in financing for continued development of PanFlu antiviral nasal spray

  The European Innovation Council Fund, Invest-NL, Gates Foundation, and ClavystBio are among those contributing to a €40 million financing to support development of Leyden Laboratories’ antiviral nasal sprays the company said. Since the beginning of… [Read more . . .]

• Pneumagen reorganizes as NorthLinks Bio to develop HEX17 mCBM nasal spray for the prevention of viral respiratory infections

  University of St Andrews spin out Pneumagen has reorganized as a US-based company called NorthLinks Bio, the company said, though research will continue in Scotland. Pneumagen CEO Douglas Thomson has joined the board of the… [Read more . . .]

• MannKind gets Breakthrough T1D grant to support trial of Afrezza insulin DPI in pediatric patients

• Kither Biotech announces results from Phase 1 trial of KIT2014 inhaled PDE3/4 inhibitor for the treatment of CF

• SpliSense gets up to $13 million in additional funding from the CFF

• Iconovo signs strategic collaboration agreement with Lonza

• FDA approves Rx to OTC switch for Amphastar’s Rextovy naloxone nasal spray

More news . . .